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Open Forum Infectious Diseases
MAJOR ARTICLE

AIDS-Defining Illnesses at Initial Diagnosis of HIV in a
Large Guatemalan Cohort
Samuel W. Reinhardt,1 Andrej Spec,2 Johanna Meléndez,3 Andrea Alonzo Cordon,3 Ian Ross,1 William G. Powderly,2 and Carlos Mejia Villatoro3,†
1
Department of Medicine and 2Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri; 3Infectious Diseases Clinic, Department of Internal Medicine,
Roosevelt Hospital, Guatemala City, Guatemala

Background. Anecdotal evidence suggests that a high proportion of patients diagnosed with HIV in Guatemala present with
AIDS. There remain limited data on the epidemiology of AIDS-defining illnesses (ADIs) in Central America.
Methods. We conducted a retrospective cohort study of all patients living with HIV at the largest HIV clinic in Guatemala.
Charts were analyzed for clinical and demographic data. Presence of an ADI was assessed by US Centers for Disease Control definitions; patients who presented with an ADI were compared with those without ADI using descriptive statistics.
Results. Of 3686 patients living with HIV, 931 (25.3%) had an ADI at HIV diagnosis, 748 (80.3%) of whom had CD4 counts
lower than 200 cells/mm3. Those with ADIs were more likely to be male (67.5% vs 54.6%; P < .0001) and heterosexual (89.4% vs
85.0%; P = .005). The most common ADIs were Mycobacterium tuberculosis (55.0%), Pneumocystis jirovecii pneumonia (13.7%),
esophageal candidiasis (13.4%), and histoplasmosis (11.4%). Histoplasmosis and HIV wasting syndrome were both more common
among rural patients.
Conclusions. In this large Guatemalan cohort of patients currently living with HIV, a significant portion presented with an ADI.
These data inform the most common ADIs diagnosed among survivors, show that histoplasmosis is more commonly diagnosed in
rural patients, and suggest that HIV wasting syndrome may reflect missed histoplasmosis diagnoses.
Keywords. AIDS; AIDS-defining illnesses; global health; Guatemala; HIV.
HIV is a significant cause of morbidity and mortality in
Guatemala, where the disease prevalence is estimated at 0.5% of
the adult population as of 2016 [1]. Patients with late presentation of HIV have higher morbidity and mortality than patients
diagnosed with less advanced disease [2]. Although modern
antiretroviral therapy (ART) was implemented in Guatemala in
the year 2000, deaths due to HIV/AIDS have risen from 13.8 per
100 000 in 1990 to 22.0 per 100 000 in 2012, and the percentage
of late presenters and those with AIDS at diagnosis is high [3].
Presence of an AIDS-defining illness (ADI) at HIV diagnosis
has been shown to increase health care costs [4]. In the United
States and Western Europe, rates of ADIs at diagnosis range
from 9.7% to 15.1% [2, 4–11]; the rates of ADIs tend to be higher
in developing countries (16.1%–28.9%) [12, 13]. Anecdotally,
the experience of HIV providers in Guatemala suggests a high
proportion of patients present with an ADI at diagnosis, but this
has yet to be the focus of a formal study.
Received 17 July 2017; editorial decision 8 November 2017; accepted 25 November 2017.
†
Deceased
Correspondence: A. Spec, MD, MSCI, Infectious Disease, Washington University School of
Medicine, 4523 Clayton Ave., Campus Box 8051, St Louis, MO 63110 (andrejspec@wustl.edu).
Open Forum Infectious Diseases®
© The Author(s) 2017. Published by Oxford University Press on behalf of Infectious Diseases
Society of America. This is an Open Access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/
by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any
medium, provided the original work is not altered or transformed in any way, and that the
work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
DOI: 10.1093/ofid/ofx249

Few studies of the distributions and prevalence of specific
ADIs exist in the developing world. A large cohort in French
Guiana showed that the most prevalent ADIs in the post-highly
active antiretroviral therapy (HAART) era were disseminated
histoplasmosis, esophageal candidiasis, cerebral toxoplasmosis,
and tuberculosis; this study also noted a decrease of HIV wasting disease and a rise in histoplasmosis when improved histoplasmosis diagnostics were introduced into the country [14].
Our current study sought to identify the proportion of currently
living patients presenting with an ADI at the time of HIV diagnosis in a large public hospital in Guatemala City, Guatemala,
and to characterize the prevalence of each ADI.
METHODS

We conducted a retrospective cohort study of all patients currently living with HIV at Roosevelt Hospital in Guatemala City,
Guatemala. Roosevelt Hospital is a large academic medical center of 900 beds in the capital city; it is publicly funded by the
national government, accepts no fees for services performed,
and predominantly serves patients with limited economic
means. The Roosevelt HIV and Infectious Diseases Clinic is
the largest HIV clinic in the country, with a census numbering
4128 active patients and approximately 500 new HIV diagnoses
each year. Inclusion criteria were patients age 18 years or older
of the Infectious Diseases Clinic at Roosevelt Hospital with a
diagnosis of HIV who were still living during the study period
and presented for a clinic visit. As all patients have a scheduled
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visit every 3 months, the study period of 4 months was intended
to capture the vast majority of the clinic census. There were
no exclusion criteria. All patients were naïve to antiretroviral
therapy at the time of diagnosis; similarly, no patients were on
antifungal therapy at the time of diagnosis. The protocol was
approved by the Roosevelt Hospital and Washington University
in St Louis institutional review boards with waiver of consent.
Charts were accessed as patients presented for routine HIV
clinic visits, and were examined for clinical and demographic
data including sex, age, sexual risk category, date of diagnosis,
region of residence in Guatemala, CD4 cell count and viral load
at time of diagnosis, presence and type of ADI, and its site at the
time of initial presentation. ADI presence was assessed using US
Centers for Disease Control and Prevention (CDC) definitions
[15]. Specific OIs were diagnosed by a combination of clinical
presentation, imaging, and microbiology where available. Cases
of histoplasmosis were confirmed by culture. Prior to 2013, cases
of tuberculosis and cryptococcal meningitis were confirmed by
culture. Starting in 2013, these cases were confirmed using mycobacterial nucleic acid amplification testing (GeneXpert) and
cryptococcal antigen assays, respectively. As HIV wasting syndrome is considered a diagnosis of exclusion, those patients who
carried a diagnosis of tuberculosis, histoplasmosis, Pneumocystis
jirovecii pneumonia, Mycobacterium avium intracellulare, cryptosporidiosis, or isosporiasis were not considered eligible for a
diagnosis of HIV wasting. If patients were charted as having both
HIV wasting syndrome and one of the aforementioned, HIV
wasting was eliminated as a diagnosis for this analysis. Patients
were considered urban dwellers if they resided in the department
of Guatemala, which contains Guatemala City and its immediate
surroundings; patients from all other departments or from other
countries were categorized as rural dwellers. Sexual risk category
was defined by the Roosevelt HIV Clinic as either heterosexual,
men who have sex with men (MSM), transgender, or sex worker.
Table 1.

Data were also collected from patients receiving new HIV diagnoses during the study period.
Data collection and survey implementation occurred during
the study period, which ran from June 1, 2015, to September
30, 2015. The on-site data collection was done using a tablet,
which allowed staff to upload de-identified clinical data and
survey responses directly to REDCap, a secure online application for collecting, storing, and transmitting data from research
studies. All transfer of information was performed through the
secure platform provided by REDCap, which was maintained by
Washington University, and data analysis was performed in the
United States.
Data analysis was performed using SPSS (IBM Corp., version 22.0). The chi-square test and the Student t test were used
for categorical and continuous variables, respectively, to assess
associations between clinical and demographic factors and the
primary outcome of ADI at HIV diagnosis. The Kruskall-Wallis
test was used to assess differences in mean CD4 and mean viral
load at diagnosis across the 3 time categories. Statistically significant associations were defined as P <.05.
RESULTS

A total of 3686 patients were enrolled during the study period.
The patients were 57.9% male with a mean age of 34.4 years, and
931 patients (25.3%) had an ADI at HIV diagnosis (Table 1).
Except for one patient diagnosed in 1998, years of HIV diagnosis ranged from 2000 to 2015. Compared with patients without
ADI at HIV diagnosis, those with ADIs were more likely to be
male (67.5% vs 54.6%; P < .0001), more likely to report a heterosexual mode of HIV acquisition (89.4% vs 85.0%; P = .005), and
were slightly older (mean age, 35.2 years vs 34.1 years; P = .009).
Mean HIV viral load (VL) at diagnosis was significantly higher
in those with ADI (403 100 vs 201 100 copies/mL, P < .0001).
Of those with ADI, 748 subjects (80.3%) had CD4 counts ≤200

Baseline Characteristics of 3686 Patients Living with HIV in Guatemala at Time of Presentation
ADI at Diagnosis (n = 931),
No. (%)

No ADI at Diagnosis (n = 2755),
No. (%)

P Value

Total Cohort (n = 3686),
No. (%)

Mean age (±SD), y

35.2 (10.3)

34.1 (11.1)

.01

34.4 (10.9)

Male sex

628 (67.5)

1505 (54.6)

<.0001

2133 (57.9)

832 (89.4)

2 342 (85.0)

3174 (86.1)

87 (9.3)

377 (13.7)

464 (12.6)

Transgender

3 (0.3)

15 (0.5)

18 (0.5)

Sex worker

9 (1.0)

21 (0.8)

30 (0.8)

Sexual risk category
Heterosexual
MSM

Mean VL at diagnosis (±SD), 1000 copies/mL

.005

403.1 (920.0)

201.1 (517.5)

CD4 count at diagnosisa

<.0001

253.0 (651.7)

<.0001

0–50

400 (43.4)

446 (16.5)

846 (23.3)

51–100

181 (19.6)

338 (12.5)

519 (14.2)

101–200

167 (18.1)

596 (22.0)

763 (21.0)

201–350

112 (12.1)

687 (25.4)

799 (22.0)

62 (6.7)

639 (23.6)

701 (19.3)

>350

Abbreviations: ADI, AIDS-defining illness; MSM, men who have sex with men; VL, viral load.
a

Of the 3628 patients (922 with ADI at diagnosis, 2706 with no ADI at diagnosis) with available CD4 count at diagnosis.
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cells/mm3, while the remaining 183 (19.7%) had CD4 counts
>200 cells/mm3.
The frequencies of individual ADIs are included in Table 2.
The most common ADIs were Mycobacterium tuberculosis
(55.0% of those with ADI at diagnosis, 13.9% of the entire
HIV cohort), Pneumocystis jirovecii pneumonia (13.7%, 3.5%),
esophageal candidiasis (13.4%, 3.4%), disseminated histoplasmosis (11.4%, 2.9%), toxoplasmosis (10.8%, 2.7%), extrapulmonary cryptococcosis (8.7%, 2.2%), and HIV wasting syndrome
(7.8%, 2.0%). Less common ADIs included HSV (7.5%, 1.9%)
and CMV retinitis (2.8%, 0.7%).
The proportion of patients presenting with an ADI at time
of HIV diagnosis was similar in urban and rural populations (P = .382) (Table 2). However, there were differences in
Table 2.

prevalence of specific ADIs. Tuberculosis was the most common ADI in both populations; however, there was a significantly
higher rate of central nervous system toxoplasmosis among the
urban patients (14.0% vs 9.2%; P = .018). Rural patients had
higher rates of histoplasmosis (13.3% vs 7.8%; P = .013) and
HIV wasting syndrome (9.2% vs 5.3%; P = .037).
Trends in the most common ADIs over time are displayed in
Table 3. Patients were grouped by year of diagnosis (1998–2005,
2006–2010, and 2011–2015). Overall incidence of any ADI at diagnosis among survivors decreased with time (P < .001). Mean CD4
count at diagnosis significantly increased with time (P < .001); mean
viral load at diagnosis also increased with time (P < .001), but only
with a magnitude of 0.1 log. There were also significant increases
over time in incidence of tuberculosis (P = .001), histoplasmosis

Frequency of AIDS-Defining Illnesses Among HIV Cohort in Guatemala
Rural Patients (n = 610),
No. (%)

Urban Patients (n = 321),
No. (%)

P Value

Patients With ADIs
(n = 931), No. (%)

Percentage of Entire HIV
Cohort (n = 3686)

Any

610 (100)

321 (100)

.378

931 (100)

25.2

Mycobacterium tuberculosis

339 (55.6)

173 (53.9)

.662

512 (55.0)

13.9

Pneumocystis jirovecii pneumonia

85 (13.9)

43 (13.4)

.835

128 (13.7)

3.5

Esophageal candidiasis

90 (14.8)

35 (10.9)

.068

125 (13.4)

3.4

Histoplasmosis

81 (13.3)

25 (7.8)

.013

106 (11.4)

2.9

Toxoplasmosis

56 (9.2)

45 (14.0)

.018

101 (10.8)

2.7

Cryptococcosis

53 (8.7)

28 (8.7)

.974

81 (8.7)

2.2

HIV wasting syndrome

56 (9.2)

17 (5.3)

.037

73 (7.8)

2.0

HSV

39 (6.4)

31 (9.7)

.07

70 (75)

1.9

CMV retinitis

17 (2.8)

9 (2.8)

.982

26 (2.8)

0.7

Recurrent bacterial infections

17 (2.8)

5 (1.6)

.243

22 (2.4)

0.6

Cryptosporidiosis

16 (2.6)

6 (1.9)

.476

22 (2.4)

0.6

7 (1.1)

0 (0)

.103

7 (0.8)

0.2

25 (4.1)

18 (5.6)

N/A

43 (4.6)

1.2

AIDS-Defining Illness

Primary CNS lymphoma
Other ADIa

There were 0 cases of Burkitt’s lymphoma, immunoblastic lymphoma, or lymphoid interstitial pneumonia.
Abbreviations: CMV, cytomegalovirus; CNS, central nervous system; HIV, human immunodeficiency virus; HSV, herpes simplex virus.
a

Other ADI includes invasive cervical cancer, recurrent pneumonia, Mycobacterium avium intracellulare, disseminated nontuberculous mycobacterium, Kaposi sarcoma, HIV encephalopathy, isosporiasis, CMV disease, recurrent Salmonella septicemia, disseminated coccidioidomycosis, progressive multifocal leukoencephalopathy, and pulmonary candidiasis.

Table 3.

Trends of CD4 Count, Viral Load, and Most Common AIDS-Defining Illnesses Over Time
Patients With ADIs From
1998–2005 (n = 776), No. (%)

Patients With ADIs From
2006–2010 (n = 1654), No. (%)

Patients With ADIs From
2011–2015 (n = 1256), No. (%)

199 (192)

188 (179)

253 (239)

<.001

217.9 (299.0)

225.0 (536.2)

309.4 (885.4)

<.001

ADI at HIV diagnosis

257 (33.1)

425 (25.7)

249 (19.8)

<.001

Mycobacterium tuberculosis

116 (45.1)

251 (59.0)

145 (58.2)

.001

Pneumocystis jirovecii pneumonia

36 (14.0)

53 (12.5)

39 (15.7)

.504

Esophageal candidiasis

45 (17.5)

49 (11.5)

31 (12.4)

.074

Histoplasmosis

17 (6.6)

50 (11.8)

39 (15.7)

.006

Toxoplasmosis

31 (12.1)

36 (8.5)

34 (13.7)

.086
.006

Mean CD4 count at diagnosisa (±SD)
Mean viral load at diagnosisb (±SD), 1000
copies/mL

P Value

Cryptococcosis

32 (12.4)

24 (5.6)

25 (10.0)

HIV wasting syndrome

19 (7.4)

43 (10.1)

11 (4.4)

.028

HSV

37 (14.4)

30 (7.1)

3 (1.2)

<.001

8 (3.1)

12 (2.8)

6 (2.4)

.89

CMV retinitis

Abbreviations: ADI, AIDS-defining illness; CMV, cytomegalovirus; HIV, human immunodeficiency virus; HSV, herpes simplex virus.
a

Of the 3628 patients with available CD4 count at diagnosis.

b

Of the 3113 patients with available viral load at diagnosis.
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Figure 1. Distribution of number of ADIs diagnosed in individual patients. This
figure shows the frequency of the number of ADIs among patients diagnosed
with at least 1 ADI at the time of HIV diagnosis (total = 931). Abbreviation: ADI,
AIDS-defining illness.

(P = .006), decreases in HIV wasting syndrome (P = .028) and herpes simplex virus (P < .001), and a change over time in cryptococcosis (P = .006) that was not consistently in one direction.
Data examining co-infection rates are displayed in Figure 1.
Of the 931 patients who were diagnosed with an ADI, 622
(66.8%) were diagnosed with a single ADI, 235 (25.2%) were
diagnosed with 2 ADIs, 63 (6.8%) were diagnosed with 3 ADIs,
4 (0.4%) were diagnosed with 4 ADIs, and 4 (0.4%) were diagnosed with 5 ADIs.
DISCUSSION

In this large cohort of living HIV patients in Guatemala, a significant proportion (25.2%) presented with an ADI at the time
of HIV diagnosis. The percentage of patients presenting with
an ADI decreased over time, a trend that was also associated
with an increase in mean CD4 at diagnosis over time. This suggests that some progress has been made in diagnosing HIV earlier among our population. While viral load at diagnosis also
increased over time and reached statistical significance, this increase was approximately 0.1 log, and therefore is of questionable clinical significance. M. tuberculosis was present in more
than half of survivors with ADI at diagnosis, which was much
higher than expected. Of note, many of the most common ADIs
in our cohort of survivors, including tuberculosis and histoplasmosis, showed a significant increase over time. We hypothesize
that this is due to a combination of improved diagnostics (as
mycobacterial GeneXpert was implemented in 2013) and survival bias (as patients with these ADIs were perhaps less likely to
survive to the study period, and ART was more readily available
in Guatemala in the later time periods). We are unaware of any
prior studies reporting the prevalence of ADIs among survivors
with HIV in Central America.
In a study of ADI distribution in French Guiana, the authors
had high suspicion that in the pre-HAART era many patients
diagnosed with HIV wasting syndrome in fact had disseminated
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histoplasmosis that was undiagnosed. In the HAART era, which
also corresponded with access to histoplasma antigen diagnostics
in French Guiana, the incidence of disseminated histoplasmosis
increased while the incidence of all other ADIs decreased [14].
It is possible, therefore, that a proportion of our cohort with
HIV wasting syndrome also represented undiagnosed disseminated histoplasmosis. The fact that both histoplasmosis and
HIV wasting syndrome were significantly higher in the rural
portion of our cohort supports this hypothesis. Improvements
in histoplasmosis diagnostics, including the enzyme-linked
immunosorbent assay developed by the CDC [16], as well as an
anticipated lateral flow assay in the near future, may prove that
histoplasmosis is a more common ADI than previously appreciated in Central America. Improved diagnostics are available
at another HIV clinic in Guatemala City, but have not been successfully implemented at Roosevelt Hospital to date [17].
The strengths of our study include the large cohort size and
the fact that it was performed in an area without previous data
on ADIs at the time of HIV diagnosis. Limitations include the
largely retrospective nature of the study (only a small percentage were new HIV diagnoses during the study period)
and the fact that it is from a single center, so the conclusions
may not be generalizable to the population of Guatemala as
a whole. Another limitation is that data were only gathered
from patients who were living during the study period and
are still receiving care. This precludes any conclusions about
the true prevalence of ADIs among HIV patients at diagnosis.
In conclusion, our study documents the significant burden of
ADIs at the time of HIV diagnosis among survivors in a large
Guatemalan cohort and identifies the most common ADIs diagnosed in this group. We show significant differences between
rural and urban populations in terms of ADIs diagnosed and
propose that histoplasmosis may play a larger role than currently estimated based on limited diagnostic capability.
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